VT-001 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 4 |
66. IgA nephropathy
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004892-41-PL (EUCTR) | 09/03/2022 | 10/01/2022 | Atacicept in Subjects with IgA Nephropathy (ORIGIN) | A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) - ORIGIN | IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT | Vera Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 2 | United States;Belarus;Czechia;Greece;Turkey;United Kingdom;India;Czech Republic;Canada;Poland;Belgium;Malaysia;Australia;Germany;Korea, Republic of | ||
| 2 | EUCTR2020-004892-41-DE (EUCTR) | 16/11/2021 | 09/06/2021 | Atacicept in Subjects with IgA Nephropathy (ORIGIN) | A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) - ORIGIN | IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT | Vera Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 2 | United States;Czechia;Greece;Turkey;United Kingdom;India;Czech Republic;Canada;Malaysia;Poland;Belgium;Australia;Germany;Korea, Republic of | ||
| 3 | EUCTR2020-004892-41-CZ (EUCTR) | 02/11/2021 | 11/05/2021 | Atacicept in Subjects with IgA Nephropathy (ORIGIN) | A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) - ORIGIN | IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT | Vera Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 2 | United States;Czechia;Greece;Turkey;United Kingdom;India;Czech Republic;Canada;Malaysia;Poland;Belgium;Australia;Germany;Korea, Republic of | ||
| 4 | EUCTR2020-004892-41-GR (EUCTR) | 06/09/2021 | 19/07/2021 | Atacicept in Subjects with IgA Nephropathy (ORIGIN) | A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Atacicept in Subjects with IgA Nephropathy (IgAN) - ORIGIN | IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Symptoms and general pathology [C23] | Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATACICEPT | Vera Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 105 | Phase 2 | United States;Czechia;Greece;Turkey;United Kingdom;India;Czech Republic;Canada;Malaysia;Poland;Belgium;Australia;Germany;Korea, Republic of |